News

/
/
OTCA25 Final Report and related documents now available

OTCA25 Final Report and related documents now available

On 17th of December 2021 EUnetHTA started an “Error reporting and correction” procedure for this assessment report. The reported potential error is under assessment by EUnetHTA and the Assessment Team. Please consult this website in January 2022 (specific date will follow) to learn more about the potential error and its impact on the report. If you have any questions, please contact EUnetHTA@zinl.nl

The final report for the Relative Effectiveness Assessment OTCA 25 “Stereotactic body radiation therapy (SBRT) for the treatment of lung, prostate and liver cancer”, is now available for access.

The aim of this HTA was to assess if the use of SBRT is more effective and safer compared to radiotherapy (RT), surgery, or surgery and conventional RT in adult patients divided into six subgroups or populations: patients with localised primary cancers (stage I or II) in (i) bronchus and lung (non-small cell lung cancer), (ii) prostate or (iii) liver, or those patients with tumours with oligometastases (stage IV) including at least one to (iv) bronchus and lung, (v) prostate or (vi) liver.

This HTA provides information on direct comparisons assessed by randomized controlled trials or nonrandomized comparative studies, considering both their effects and information on quality of the related evidence.

Please access all documentation for OTCA25 at the following links:

OTCA25 Final Report

OTCA25 Comments from External Experts and Manufacturers

OTCA25 Final Project Plan

OTCA25 Comments from External Experts

This website uses cookies to ensure you get the best experience on our website. By using the website you agree to our Privacy Policy and our Terms of Use.